FDA Approves Incyte Drug for Rare Skin Cancer Merkel Cell Carcinoma

Regulatory approval of Incyte’s cancer immunotherapy, Zynyz, comes two years after the FDA rejected an application seeking approval in a rare type of anal cancer.